Press release year list 2021 2020 2019 2018
07/23/2021
Brooklyn Immuno Reports Inducement Grants
07/19/2021
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
07/13/2021
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
07/12/2021
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
07/06/2021
Brooklyn ImmunoTherapeutics Reports Inducement Grants
06/14/2021
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
06/09/2021
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index
06/08/2021
Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer
06/02/2021
Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts
05/26/2021
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call
05/24/2021
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing
05/21/2021
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
05/18/2021
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET
05/13/2021
Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
05/11/2021
Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research
05/07/2021
Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics
04/29/2021
Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders
04/26/2021
Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics
04/19/2021
Brooklyn ImmunoTherapeutics Reports Inducement Grants
04/16/2021
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders
04/15/2021
Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc.
04/06/2021
Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.
03/25/2021
Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime
02/09/2021
Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer